NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas

Patients with neurofibromatosis type 1 (NF1) frequently develop plexiform neurofibromas (PNs), which can cause significant morbidity. We performed a phase II trial of the MAPK/ERK kinase inhibitor, mirdametinib (PD-0325901), in patients with NF1 and inoperable PNs. The primary objective was response...

Full description

Saved in:
Bibliographic Details
Published in:J Clin Oncol
Main Authors: Weiss, Brian D., Wolters, Pamela L., Plotkin, Scott R., Widemann, Brigitte C., Tonsgard, James H., Blakeley, Jaishri, Allen, Jeffrey C., Schorry, Elizabeth, Korf, Bruce, Robison, Nathan J., Goldman, Stewart, Vinks, Alexander A., Emoto, Chie, Fukuda, Tsuyoshi, Robinson, Coretta T., Cutter, Gary, Edwards, Lloyd, Dombi, Eva, Ratner, Nancy, Packer, Roger, Fisher, Michael J.
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2021
Subjects:
Original Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8078274/
https://ncbi.nlm.nih.gov/pubmed/33507822
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02220
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items